In a single-arm early trial at two Belarusian centres, a CD19 CAR T-cell product made in Belarus treated 23 children and adults with relapsed B-cell cancers; 16 of 20 who could be assessed responded.
Published as "CD19 CAR T cell therapy BY19 for pediatric and adult patients with relapsed or refractory B cell neoplasms in Belarus: Phase 1 trial". A single-arm, open-label phase 1 trial (NCT05333302) of an in-house manufactured CD19 CAR T-cell product, BY19, after lymphodepletion with fludarabine and cyclophosphamide, with or without decitabine. Authors are from the Vitebsk Regional Clinical Cancer Centre, the Institute of Bioorganic Chemistry of the National Academy of Sciences and the Belarusian Research Center for Pediatric Oncology, Hematology and Immunology.
Making CAR T cells locally can bring this treatment to patients in middle-income countries where commercial products are out of reach, with safety and efficacy the authors judge comparable to approved products.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/